Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.

Our study suggests risk among younger ranolazine patients is rare. Given the imprecision of the risk estimates, we interpret the elevated seizure risk following ranolazine exposure with caution. Further analysis in a larger elderly population is warranted.